MAP2K7 and colorectal carcinoma: As has been reported by us and others, resistance to MEK inhibition in CRC is multifactorial and related to secondary mutation events, feedback loops, or compensatory pathway activation, all of which require improved detection methodology so that combination therapy can be individualized [15, 31].